Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥20.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥6.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.3bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥6.4bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.3bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.2bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥554m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.8bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥790m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥48.5bnat 2023-09-30Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥36.5bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥21.9bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥26.6bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥24.2bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥18.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥4.4bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.7bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥5.0bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥46.612023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.682023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥46.132023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.332023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio50.0%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥24m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-09-30¥888m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-09-30¥5.9bn
—segment totalrevenue2023-01-01 → 2023-09-30¥20.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥20.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥24m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 682
ItemContextValueUnit
Equity IFRSPrior1YearInstant19810968000JPY
Equity IFRSCurrentQuarterInstant26586611000JPY
Liabilities and equity IFRSPrior1YearInstant33906981000JPY
Liabilities and equity IFRSCurrentQuarterInstant48468006000JPY
Revenue IFRSPrior1YTDDuration12761031000JPY
Revenue IFRSCurrentYTDDuration20547895000JPY
Cost of sales IFRSPrior1YTDDuration1907239000JPY
Cost of sales IFRSCurrentYTDDuration2369420000JPY
Gross profit IFRSPrior1YTDDuration10853792000JPY
Gross profit IFRSCurrentYTDDuration18178475000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration7498561000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration9556455000JPY
Research and development expenditure recognized as expense during period IFRSPrior1YTDDuration1819132000JPY
Research and development expenditure recognized as expense during period IFRSCurrentYTDDuration1776530000JPY
Other income IFRSPrior1YTDDuration82623000JPY
Other income IFRSCurrentYTDDuration358417000JPY
Other expenses IFRSPrior1YTDDuration124524000JPY
Other expenses IFRSCurrentYTDDuration401369000JPY
Operating profit loss IFRSPrior1YTDDuration1494197000JPY
Operating profit loss IFRSCurrentYTDDuration6802536000JPY
Finance income IFRSPrior1YTDDuration347752000JPY
Finance income IFRSCurrentYTDDuration505384000JPY
Finance costs IFRSPrior1YTDDuration618870000JPY
Finance costs IFRSCurrentYTDDuration904311000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration－JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-27537000JPY
Profit loss before tax IFRSPrior1YTDDuration1223079000JPY
Profit loss before tax IFRSCurrentYTDDuration6376072000JPY
Income tax expense IFRSPrior1YTDDuration898662000JPY
Income tax expense IFRSCurrentYTDDuration1571575000JPY
Profit loss IFRSPrior1YTDDuration324416000JPY
Profit loss IFRSCurrentYTDDuration4804496000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration1076065000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration2213274000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration-751649000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration2591222000JPY
Basic earnings loss per share IFRSPrior1YTDDuration22.67
Basic earnings loss per share IFRSCurrentYTDDuration46.61
Diluted earnings loss per share IFRSPrior1YTDDuration22.46
Diluted earnings loss per share IFRSCurrentYTDDuration46.13
Revenue IFRSPrior1QuarterDuration4606213000JPY
Revenue IFRSCurrentQuarterDuration6451350000JPY
Cost of sales IFRSPrior1QuarterDuration772584000JPY
Cost of sales IFRSCurrentQuarterDuration1028205000JPY
Gross profit IFRSPrior1QuarterDuration3833629000JPY
Gross profit IFRSCurrentQuarterDuration5423144000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration2732811000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration3377271000JPY
Research and development expenditure recognized as expense during period IFRSPrior1QuarterDuration729592000JPY
Research and development expenditure recognized as expense during period IFRSCurrentQuarterDuration523471000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass